-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed -Carol Vallone appointed as Chair of the Board of Directors, Andreas Krebs appointed as Vice Chair and Perry Dellelce transitions from his role as Chairman- NEW YORK, Dec. 14, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”)…

Source

Previous articleField Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality
Next articleatai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia